Discontinued — last reported Q4 '24
Reblozyl — Sales
Merck & Co. Reblozyl — Sales remained flat by 0.0% to $185.50M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 251.7%, from $52.75M to $185.50M. Over 3 years (FY 2021 to FY 2024), Reblozyl — Sales shows an upward trend with a 179.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests strong market demand, successful physician adoption, or expanded patient access, while a decrease may indicate increased competition, patent expirations, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total net revenue generated from the sale of the pharmaceutical product Reblozyl. It reflects...
Peer comparison
Comparable to revenue metrics for specific blockbuster or specialty drugs in the portfolios of other large-cap pharmaceutical companies.
mrk_segment_reblozyl_salesHistorical Data
| FY'21 | FY'22 | FY'23 | FY'24 | |
|---|---|---|---|---|
| Value | $34.00M | $332.00M | $211.00M | $742.00M |
| YoY Change | — | +876.5% | -36.4% | +251.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s reblozyl — sales?
- Merck & Co. (MRK) reported reblozyl — sales of $185.50M in Q4 2024.
- How has Merck & Co.'s reblozyl — sales changed year-over-year?
- Merck & Co.'s reblozyl — sales increased by 251.7% year-over-year, from $52.75M to $185.50M.
- What is the long-term trend for Merck & Co.'s reblozyl — sales?
- Over 3 years (2021 to 2024), Merck & Co.'s reblozyl — sales has grown at a 179.5% compound annual growth rate (CAGR), from $34.00M to $742.00M.
- What does reblozyl — sales mean?
- The total revenue generated from the sales of the Reblozyl pharmaceutical product.